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Objectives This study investigated the effects of rosiglitazone (RSG) on left ventricular ejection fraction (LVEF) in subjects
with type 2 diabetes (T2DM) and pre-existing chronic heart failure (CHF) (New York Heart Association [NYHA]
functional class I to II).
Background Fluid retention is an important consideration in the use of thiazolidinediones in T2DM patients because it could
exacerbate symptoms or precipitate decompensation in those with previously stable CHF.
Methods A total of 224 patients with T2DM and NYHA functional class I to II CHF with LVEF 45% were randomized to a
52-week treatment with RSG (4 to 8 mg daily, n  110) or placebo (PLB) (n  114) in addition to background
antidiabetes therapy. Treatment was uptitrated to achieve target fasting plasma glucose 126 mg/dl; CHF med-
ications were adjusted as appropriate.
Results The LVEF was similar in both groups at baseline (RSG 35.3 6.2%, PLB 35.7  7.8%) and after 52 weeks of treat-
ment (mean difference 1.49%, p  0.1). Glycemic control was significantly better in the RSG group (mean difference
in hemoglobin A1c 0.65%, p  0.0001). There were significantly more adjudicated events in the RSG group of new
or worsening edema (RSG n  28 [25.5%]; PLB n  10 [8.8%]; p  0.005) and increased CHF medication (RSG n
36 [32.7%], PLB n  20 [17.5%]; p  0.037), but no significant difference between groups for other adjudicated end
points. A similar proportion of patients withdrew from each treatment group because of adverse events.
Conclusions After 52 weeks of treatment, RSG improved glycemic control but did not adversely affect LVEF in patients with
T2DM and NYHA functional class I to II CHF. More fluid-related events occurred with RSG, although these gener-
ally did not lead to withdrawal from the study. (J Am Coll Cardiol 2007;49:1696–704) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.077s
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Chronic heart failure (CHF) is common in
patients with type 2 diabetes mellitus (T2DM)
and is associated with considerable morbidity
and mortality (1). The poor prognosis in patients
with T2DM and CHF has been attributed to
increased myocardial hypertrophy, myocardial fibro-
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r. Wilding received a GlaxoSmithKline investigator research grant for study 2is (2), and abnormal cardiac metabolism, which may contribute to
he development of myocardial ischemia, worsening ventricular
ysfunction, and arrhythmias (3). To prevent complications in
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April 24, 2007:1696–704 Rosiglitazone and NYHA Class I or II CHFatients with T2DM, treatment has focused on the manage-
ent of concomitant risk factors and on improving glycemic
ontrol (4).
Thiazolidinediones such as rosiglitazone (RSG) are per-
xisome proliferator-activated receptor- agonists that im-
rove insulin sensitivity in the liver, muscle, and adipose
issue (5,6), resulting in improved glycemia. A potential
imiting factor for the use of thiazolidinediones in CHF
atients is their tendency to cause fluid retention. This can
ead to the development of peripheral edema, although this
ay not necessarily represent deterioration in cardiac func-
ion. Symptomatic heart failure can be precipitated or
xacerbated because of plasma volume expansion in patients
ith impaired ventricular function (7).
A key question that remains unanswered, despite the
resence of anecdotal reports and observational studies
8–12), is whether RSG can be administered safely to
atients with established CHF that is mild to moderate in
everity, and what effect it has on cardiac function in these
atients. The primary goal of this study was to investigate
he effects of treatment with RSG for a period of 1 year on
ardiac structure and function as determined by echocardi-
graphy (ECHO) in T2DM patients with New York Heart
ssociation (NYHA) functional class I to II CHF. The
econdary objectives were to evaluate the extent of RSG-
nduced fluid retention in this potentially at-risk population
nd assess its impact on clinical status.
ethods
his was a 52-week, multicenter, double-blind, randomized,
lacebo-controlled, parallel group study in patients with
2DM and mild to moderate stable CHF (NYHA functional
lass I to II). Ethical approval was obtained in each of the 14
uropean countries that participated in the study, and all
atients gave written informed consent. The study was funded
y GlaxoSmithKline (protocol 49653/211).
Patients were required to have inadequate glycemic con-
rol at screening (fasting plasma glucose 126 mg/dl [7
mol/l] and 216 mg/dl [12 mmol/l]) and could be
eceiving any antidiabetes treatment except for a thiazo-
idinedione, insulin, or combination therapy with an insulin
ecretagogue and acarbose. Only stable patients in NYHA
unctional class I to II CHF were included, and all had to be
reated with an angiotensin-converting enzyme inhibitor or
ngiotensin receptor blocker. In addition, patients with
YHA functional class II CHF had to be treated with a
iuretic. According to recommended practice at the incep-
ion of the study, patients were not required to be on a
eta-blocker. All patients were required to have a left
entricular ejection fraction (LVEF) 45%. Patients were
xcluded if they had a body mass index 35 kg/m2,
reatinine clearance 40 ml/min (calculated using the
ockcroft-Gault equation adjusted for ideal body weight),
ignificant hepatic disease, or laboratory-confirmed anemia
hemoglobin 11 g/dl for men and 10 g/dl for women). tAfter a 4-week, single-blind
un-in period on placebo (PLB)
nd background antidiabetes
herapy, eligible patients, strati-
ed by NYHA functional class at
creening, entered the 52-week
ouble-blind period. Patients
ere randomized in a 1:1 ratio
sing a computer-generated fixed
lock size of 4, initially receiving
evel 1 study medication (RSG
mg once daily or PLB once
aily) in addition to background
ntidiabetes therapy.
djustment of study medication
nd background oral antidiabe-
es medication. Throughout the
tudy, patients were treated to a
arget fasting plasma glucose level
126 mg/dl (7 mmol/l) by upti-
rating to Level 2 study medication
RSG 4 mg twice daily or PLB
wice daily). At week 52, 56 pa-
ients (69%) in the RSG group
ere taking the maximal (8 mg)
ose. If glycemic control was still
nadequate at or beyond week 16,
dditional oral antidiabetes agents, with the exception of
etformin and insulin, could be prescribed. Patients were
ithdrawn from the study if fasting plasma glucose was 270
g/dl (15 mmol/l) during the first 16 weeks of treatment or
216 mg/dl (12 mmol/l) thereafter on 2 consecutive occa-
ions. Unless the patient had been prematurely withdrawn
rom the study, each case was reviewed at least every 4 weeks
ntil week 20 and every 8 weeks thereafter.
CHO and laboratory assays. The ECHOs were per-
ormed on all patients within 7 days of screening and in the 7
ays before or at week 28 and week 52. If patients were
ithdrawn from the study prematurely, an ECHO was per-
ormed at or within 7 days of the early withdrawal visit. A
tandard ECHO examination was performed in the left lateral
ecubitus position after 5 min rest, to assess left ventricular
unction. At least 15 cardiac cycles for both the apical 4- and
-chamber views were obtained during quiet respiration (13).
All ECHOs were read centrally in a blinded manner.
aw videotape images were analyzed with a TomTec P90
version 2.2) offline ECHO analyzer (TomTec Imaging
ystems GmbH, Munich, Germany). The biplane disc
ummation method (Simpson rule) for the apical 2- and
-chamber views was used to determine left ventricular
nd-diastolic volume index (LVEDVI), left ventricular
nd-systolic volume index (LVESVI), and LVEF (13). If
he LVEF on the screening ECHO was 45%  6.5%
hen analyzed by the central ECHO reader, patients were
xcluded from the study. The figure of 6.5% was based on
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CHF  chronic heart failure
ECHO  echocardiogram/
echocardiography
EE  efficacy evaluable
ITT  intent-to-treat with
last observation carried
forward
LVEDVI  left ventricular
end-diastolic volume index
LVEF  left ventricular
ejection fraction
LVESVI  left ventricular
end-systolic volume index
LVMI  left ventricular
mass index
NYHA  New York Heart
Association
PLB  placebo
RSG  rosiglitazone
T2DM  type 2 diabetes
mellitushe standard deviation of the mean LVEF from former
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Rosiglitazone and NYHA Class I or II CHF April 24, 2007:1696–704tudies performed at the core laboratory. Left ventricular
ass index (LVMI) was determined using left ventricular
ass (American Society of Echocardiography criteria [13])
ivided by body surface area. Cardiac index was determined
s: heart rate  (LVEDVI  LVESVI)/(1,000  body
urface area). The transmitral Doppler flows were measured
rom the apical 4-chamber view by placing the sample
olume at the leaflet tips of the open mitral valve. The peak
elocities of 3 sequential E and A waves were recorded.
ransmitral Doppler waveforms were considered unsuitable
or analysis if the angle between the cursor and the direction
f flow was 30°, the sample volume was inadequately
ositioned, the Doppler signal was weak/indistinct, or the
eart rate was 100 beats/min. The E:A ratio was calcu-
ated by dividing the mean E-wave velocity by the mean
-wave velocity. Isovolumic relaxation time was measured
n the spectral Doppler trace as the time from aortic valve
losure to mitral valve opening on 3 sequential waveforms.
he E-wave deceleration time was measured as the time
rom peak velocity to baseline of the E-wave in 3 sequential
aveforms.
Blood samples were taken at baseline and at each study
isit. Hemoglobin (Hb) A1c was determined using a Bio-Rad
ariant II (Bio-Rad Laboratories, Hercules, California) and
eported as DCCT (Diabetes Control and Complications
rial)-aligned values. Brain natriuretic peptide (BNP) concen-
ration was determined by nonextraction radioimmunoassay
Peninsula Laboratories, San Carlos, California).
linical end points. All potential clinical end points were
eported to an independent clinical end point committee
onsisting of 3 consultant cardiologists. The occurrence of
n end point was determined by the committee from
nformation provided by the study centers and from avail-
ble hospital records.
LL-CAUSE MORTALITY. The clinical end point committee
lassified all deaths as either cardiovascular or noncardio-
ascular. In the absence of a definite noncardiovascular
ause, death was defined as being cardiovascular. Events
ncluded were sudden death; death caused by myocardial
nfarction, heart failure, or stroke; death caused by a
ardiovascular investigation, procedure, or operation; or
nother specific cardiovascular cause.
ARDIOVASCULAR HOSPITALIZATION. A similar approach
as adopted for cardiovascular hospitalization, defined as
vernight hospitalization for a cardiovascular reason.
EFINITE WORSENING OF CHF. This was defined as an
vernight admission to hospital plus 1 criterion from each of
he 4 following groups: 1) new or worsening symptoms
dyspnea during exercise, dyspnea at rest, paroxysmal nocturnal
yspnea); 2) physical examination signs (rales, S3 gallop,
dema, elevated jugular venous distension); 3) relevant findings
n investigation (chest radiograph, ECHO, worsening LVEF,
emodynamic changes); and 4) changes in the current treat-
ent or the addition of new medications for CHF. mOSSIBLE WORSENING OF CHF. This was defined as: 1)
igns and symptoms of worsening CHF (as previously
oted); 2) a supporting investigation (as previously noted);
nd 3) a change in medication for CHF. Admission to
ospital was not required. All potential cases were consid-
red by the clinical end point committee.
EW OR WORSENING EDEMA/DYSPNEA. New or worsening
dema/dyspnea was defined as investigator-reported devel-
pment of new edema/dyspnea during the study or the
orsening of the severity (mild, moderate, severe) of exist-
ng edema/dyspnea compared with baseline. Patients who
ad an adjudicated event of new or worsening edema/
yspnea could also have an adjudicated event of definite or
ossible worsening of CHF provided the additional criteria
iscussed above were met.
NCREASE IN CHF MEDICATION. Increase in CHF medica-
ion was defined as any increase in the total daily dose of any
edications taken at screening or the addition of new
edications for the treatment of CHF during the study.
his could include any medication prescribed as treatment
or fluid retention or CHF, especially diuretics.
tudy populations. The intent-to-treat with last observation
arried forward (ITT) population included all randomized
atients who had at least 1 valid post-baseline observation for
n efficacy variable while on randomized treatment. Baseline
easurements were not carried forward. The efficacy evaluable
EE) population consisted of all randomized patients who had
t least 1 valid post-baseline observation for an efficacy variable
hile on randomized treatment and who did not have a major
rotocol violation. Major protocol violations included the use
f insulin, an increase in dose or initiation of a beta-blocker, or
n acute cardiac event within 1 month before a scheduled
CHO. The EE population was determined before the study
as unblinded. The adjudicated clinical end point data in-
luded all patients who had received at least 1 dose of
ouble-blind study medication.
rimary end point. The hypothesis to be tested was that
SG was noninferior to PLB with respect to change from
aseline to week 52 in LVEF in the EE population.
econdary end points. The hypothesis that RSG was supe-
ior to PLB in the change from baseline to week 52 in LVEF
as tested in the ITT population. Other secondary end points
ncluded the between- and within-treatment group differences
n the ITT population for LVEDVI, LVESVI, LVMI,
ardiac index, E:A ratio, E-wave deceleration time, isovolumic
elaxation time, HbA1c, and BNP. Although the study was
ot powered to detect statistically significant differences be-
ween the treatment groups, the incidence of adjudicated
linical end points in each treatment group from the entire
andomized population was assessed.
tatistical analyses. As defined a priori in the protocol, an
nalysis of covariance procedure was carried out (PROC
IXED in SAS, SAS Institute Inc., Cary, North Carolina)
sing terms for treatment, center, body mass index, baseline
easurement, and NYHA functional class (I to II). For the
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April 24, 2007:1696–704 Rosiglitazone and NYHA Class I or II CHFhange in LVEF from baseline to week 52, a 95% confi-
ence interval (2-sided) based on the above model for the
ifference in treatment means (RSG vs. PLB) was con-
tructed. If the lower limit of this confidence interval was
reater than 3.5 percentage units in the EE population,
SG was deemed to be noninferior to PLB. The limit of
3.5% was judged to be a clinically meaningful difference in
VEF between treatment groups. As defined a priori in the
rotocol, the assessment of incidence of specific cardiovas-
ular morbidity and mortality end points (Table 1) was
ompared between treatment regimens using a proportional
azard regression model (PROC PHREG in SAS) with
aseline HbA1c, body mass index, and NYHA functional
lass (I to II) as covariates. Additionally, similar post hoc
nalyses were performed on the end points shown in Table 2.
esults
n total, 377 patients from 77 European centers were
creened for entry into the study, with 224 patients from 67
uropean centers subsequently randomized to receive
ouble-blind medication (PLB n  114, RSG n  110)
see Appendix). Of the patients who were screened but not
andomized, most failed to meet the study inclusion/
xclusion criteria (148 of 153; 96.7%).
The demographic characteristics for the ITT population
ere similar between treatment groups and are summarized
n Table 3. Baseline glycemic control and the duration of
HF were well matched in both treatment groups, but the
roportion of patients in NYHA functional class II was
lightly higher in the RSG group. These characteristics of
he EE population were similar to those of the ITT
opulation.
The most commonly reported cardiovascular conditions
t screening are summarized in Table 4. The spectrum of
Time-to-Event Analysis of Major Adjudicated Clin
Table 1 Time-to-Event Analysis of Major Adj
Adjudicated End Point
PLB, n  114
n (%)
All-cause mortality or worsening CHF 8 (7.5)
All-cause mortality 5 (4.8)
CV death 4 (3.8)
Data adjusted for withdrawals. *Hazard ratio is the ratio of RSG haza
CHF  chronic heart failure; CI  confidence interval; CV  cardiov
roportion of Patients Withther Adjudicated Clinical End Points
Table 2 Proportion of Patients WithOther Adjudicated Clinical End Points
Adjudicated End Point
PLB, n  114
n (%)
RSG, n  110
n (%) p Value
Cardiovascular hospitalization 15 (13.2) 21 (19.1) 0.465
Definite worsening CHF 4 (3.5) 5 (4.5) 0.858
Possible worsening CHF 0 2 (1.8) –*
New or worsening edema 10 (8.8) 28 (25.5) 0.005
New or worsening dyspnea 19 (16.7) 29 (26.4) 0.197
Increase in CHF medication 20 (17.5) 36 (32.7) 0.037No events occurred in 1 treatment group, preventing analysis using this model.
Abbreviations as in Table 1. Hndividual conditions was similar in both groups, but the
revalence of previous myocardial infarction was higher in
he RSG group, although unexpectedly low for this popu-
ation. The overall rate of coronary heart disease (which
ncludes a reported history of ischemic heart disease, angina,
nd myocardial infarction) was slightly higher in the RSG
roup (53 patients, 48.2%) compared with the PLB group
47 patients, 41.2%).
The proportion of patients who received antidiabetes
edication in the 90 days before screening was similar in
oth groups (Table 5). The most commonly received
edications were glibenclamide and metformin. In addition
o angiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers, which were mandatory, the most fre-
uently reported cardiovascular medications in both groups
ere aspirin and loop diuretics (Table 5). Although not
andated, beta-blockers were being taken by 70% of
atients, and equivalent proportions of patients were being
reated with loop diuretics, aspirin, and statins in each
reatment group.
End Points
ted Clinical End Points
RSG, n  110
n (%) Hazard Ratio* (95% CI), p Value
11 (10.6) 1.283 (0.513–3.209), 0.59
8 (7.7) 1.495 (0.487–4.593), 0.48
5 (4.8) 1.134 (0.303–4.254), 0.85
to control hazard rate.
; PLB  placebo; RSG  rosiglitazone.
ummary of Demographic and Baselineharacteristics (Intent-to-Treat Patie ts)
Table 3 Summary of Demographic and BaselineCharacteristics (Intent-to-Treat Patients)
Demographic Characteristic
PLB, n  110
n (%)
RSG, n  108
n (%)
Age (yrs) 63.9 8.6 64.3 8.8
Gender (% male) 79.1 84.3
Race, n (%)
White 109 (99.1) 107 (99.1)
Asian 1 (0.9) 0
Other 0 1 (0.9)
Current smokers 21 (19.1) 23 (21.3)
BMI (kg/m2) 28.6 3.5 28.8 3.7
Weight (kg) 84.3 14.3 84.9 14.8
Waist:hip ratio 0.96 0.12 0.98 0.14
Baseline HbA1c (%) 7.8 1.3 7.8 1.3
Baseline FPG (mg/dl) 163.3 45.7 163.6 42.8
Number of years with diabetes* 4 (0–29) 4.5 (0–30)
Baseline creatinine (mol/l) 83.9 25.3 90.4 34.2
Baseline hemoglobin (g/dl) 14.0 1.2 14.3 1.4
Baseline hematocrit (%) 42.1 3.8 42.7 4.2
Number of years with CHF* 3 (0–19) 3 (0–33)
NYHA functional class, n (%)
I 48 (43.6) 38 (35.2)
II 62 (56.4) 70 (64.8)
ata expressed as mean  SD as appropriate. *Data expressed as median (range).ical
udicaBMI  body mass index; FPG  fasting plasma glucose; Hb  hemoglobin; NYHA  New York
eart Association; other abbreviations as in Table 1.
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Rosiglitazone and NYHA Class I or II CHF April 24, 2007:1696–704Baseline ECHO parameters were similar in both treat-
ent groups (Table 6). In both groups, the mean LVEF
as 40%, thus fulfilling the a priori definition of systolic
eart failure; left ventricular volumes were also increased.
he LVEF was similar in the EE and ITT populations.
Of the 224 patients randomized, 62 (27.7%) withdrew
uring the double-blind treatment period. The withdrawal
ate was similar in the RSG and PLB groups (RSG 30
atients [27.3%], PLB 32 patients [28.1%]). The primary
eason for withdrawal in both groups was adverse events
RSG 14 patients [12.7%], PLB 12 patients [10.5%]).
hese included CHF/edema (RSG 3 patients, PLB 3
atients), stroke/transient ischemic attack (RSG 1 patient,
LB 2 patients), myocardial infarction/angina (RSG 0
atients, PLB 1 patient), ventricular tachycardia (RSG 1
atient, PLB 0 patients), ventricular fibrillation (RSG 1
atient, PLB 0 patients), and sudden death (RSG 0 pa-
ients, PLB 1 patient). In the PLB group, 9 patients (7.9%)
ithdrew because of an insufficient therapeutic response,
ompared with 2 patients (1.8%) in the RSG group.
CHO and laboratory end points. With respect to the
hange in LVEF from baseline to week 52 in the EE
opulation, RSG was noninferior to PLB (i.e., the lower
ound of the 95% confidence interval was greater than
3.5%) (Table 6). There was no significant between-
reatment difference in the change in LVEF in the ITT
opulation (Table 6), although there was a small significant
ncrease from baseline in LVEF in the RSG group. There
ere no significant between-treatment differences for
VEDVI, LVESVI, or cardiac index in the ITT population
Table 6). Approximately one-third of the patients had
valuable data at baseline and follow-up to permit the
easurement of LVMI; there were no between-group
ifferences or changes from baseline in LVMI. The E:A
atio decreased from baseline with PLB but remained
nchanged with RSG (Table 6). No changes from baseline
r between-group differences were observed for E-wave
ardiovascular Conditions Reported by >5% of Allnd mized Patie ts n Eith r Treatmentroup at Baselin
Table 4
Cardiovascular Conditions Reported by >5% of All
Randomized Patients in Either Treatment
Group at Baseline
Medical Condition by Preferred Term
PLB, n  114
n (%)
RSG, n  110
n (%)
Ischemic heart disease 40 (35.1) 40 (36.4)
Angina pectoris 21 (18.4) 23 (20.9)
Myocardial infarction 4 (3.5) 7 (6.4)
Hypertension 42 (36.8) 35 (31.8)
Essential hypertension 18 (15.8) 12 (10.9)
Cholesterol/triglycerides elevated 24 (21.1) 27 (24.5)
Hyperlipidemia 19 (16.7) 21 (19.1)
Conduction disorder 16 (14.0) 13 (11.8)
Atrial fibrillation 9 (7.9) 8 (7.3)
Atrioventricular block 1 (0.9) 7 (6.4)
Primary cardiomyopathy 7 (6.1) 6 (5.5)
LB  placebo; RSG  rosiglitazone.eceleration time or the isovolumic relaxation time. dAlthough a goal of the study was to achieve similar
lycemic control in both treatment groups, after 52 weeks of
reatment, HbA1c was significantly lower in the RSG
roup, (7.3 1.2%) compared with PLB (8.0 1.4%). The
djusted mean difference between the treatment groups was
0.65% (95% confidence interval 0.94 to 0.37),
 0.0001. For both groups of patients, and irrespective of
YHA functional class, there was no correlation between
hanges in HbA1c and changes in LVEF (class I: r 
0.08, p  0.48; class II: r  0.08, p  0.41).
At week 52, serum BNP had increased from baseline in
he RSG group (geometric mean percentage change from
aseline 57.5%, 95% confidence interval 25.9 to 97.0,
 0.0001). However, there was no significant difference in
ean BNP concentration between groups (p 0.08) (Fig. 1).
ummary of Previous Antidiabetes andV Medications (All Ra domiz d P tients)
Table 5 Summary of Previous Antidiabetes andCV Medications (All Randomized Patients)
Medication
PLB, n  114
n (%)
RSG, n  110
n (%)
Antidiabetes medications
Glibenclamide 39 (34.2) 42 (38.2)
Metformin 35 (30.7) 24 (21.8)
Gliclazide 12 (10.5) 22 (20.0)
Glimepiride 16 (14.0) 14 (12.7)
No previous antidiabetes
medication (treated
with diet and exercise)
21 (18.4) 17 (15.5)
CHF medications
ACEI* 94 (82.5) 96 (87.3)
ARB* 17 (14.9) 16 (14.5)
Beta-blockers
Selective 47 (41.2) 38 (34.5)
Nonselective 34 (29.8) 38 (34.5)
Diuretics
Loop 67 (58.8) 70 (63.6)
Spironolactone 19 (16.7) 24 (21.8)
Thiazide 20 (17.5) 15 (13.6)
Potassium-sparing 5 (4.4) 4 (3.6)
Digoxin 28 (24.6) 29 (26.4)
Other CV medications
Aspirin 73 (64.0) 69 (62.7)
Antiplatelet 4 (3.5) 9 (8.2)
Nitrates 37 (32.5) 31 (28.2)
Calcium antagonists
DHP 8 (7.0) 14 (12.7)
Non-DHP 0 2 (1.8)
Antiarrhythmics 7 (6.1) 3 (2.7)
Statins 50 (43.9) 48 (43.6)
Other lipid-lowering agent 1 (0.9) 0
Fibrate 4 (3.5) 3 (2.7)
Warfarin 21 (18.4) 19 (17.3)
Vasodilator 16 (14.0) 11 (10.0)
Alpha-blockers 0 3 (2.7)
ome patients were prescribed more than 1 cardiovascular medication. *Three patients included
n the PLB group did not take an ACEI or ARB on entry into the study.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; DHP 
ihydropyridine; other abbreviations as in Table 1.
Mean Values of Echocardiographic Parameters at Baseline and Week 52
Table 6 Mean Values of Echocardiographic Parameters at Baseline and Week 52
Parameter
PLB RSG
Adjusted Mean Difference From
PLB at 52 Weeks (95% CI)Baseline Week 52 Change From Baseline Baseline Week 52 Change From Baseline
LVEF (%), EE population 35.7 7.8 (n 70) 36.8 8.4 1.1 5.6 35.3 6.2 (n 65) 37.8 6.5 2.5 5.5 1.49 (0.32 to 3.30), p 0.1
p  0.09 p  0.001
LVEF(%), ITT population 36.3 7.7 (n 94) 37.1 8.4 0.8 5.9 34.1 7.4 (n 84) 36.3 7.5 2.2 5.6 1.42 (0.21 to 3.04), p 0.09
p  0.2 p  0.001
LVEDVI (ml/m2) 69.3 32.5 (n 94) 69.1 30.4 0.2 17.6 76.4 29.1 (n 83) 75.5 30.4 1.0 18.6 1.23 (4.05 to 6.51), p 0.7
p  0.8 p  0.6
LVESVI (ml/m2) 45.5 25.8 (n 94) 45.2 25.4 0.3 13.6 51.7 25.8 (n 83) 49.7 26.6 2.0 14.9 0.57 (4.75 to 3.62), p 0.8
p  0.8 p  0.2
LVMI (g/m2) 189.2 58.5 (n 34) 195.5 70.1 6.4 45.8 185.6 50.3 (n 27) 190.1 38.7 4.4 44.4 5.83 (30.69 to 19.03), p 0.6
p  0.4 p  0.6
Cardiac index 1.64 0.74 (n 88) 1.66 0.68 0.01 0.51 1.69 0.45 (n 78) 1.73 0.43 0.03 0.49 0.06 (0.08 to 0.20), p 0.4
p  0.8 p  0.5
E:A ratio 1.32 0.81 (n 73) 1.12 0.65 0.20 0.57 1.23 0.83 (n 73) 1.37 0.95 0.14 0.75 0.30 (0.11 to 0.49), p 0.003
p  0.004 p  0.1
E-wave deceleration time (ms) 161.8 46.1 (n 86) 161.3 60.9 0.5 61.5 159.5 53.3 (n 82) 161.1 54.8 1.5 54.8 2.1 (14.1 to 18.3), p 0.8
p  0.9 p  0.8
Isovolumic relaxation time (ms) 86.0 21.5 (n 70) 88.0 19.3 2.0 20.0 94.9 20.0 (n 62) 90.4 19.7 4.6 18.9 1.20 (6.71 to 4.32), p 0.7
p  0.4 p  0.06
Data expressed as mean  SD. The number (n) of patients within each group for each parameter is indicated in parentheses.
EE  efficacy evaluable; ITT  intent-to-treat; LVEDVI  left ventricular end-diastolic volume index; LVEF  left ventricular ejection fraction; LVESVI  left ventricular end-systolic volume index; LVMI  left ventricular mass index; other abbreviations as in Table 1.
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nces for any clinical outcomes analyzed as time to first
vent (Table 1). A similar number of patients in both groups
ad an adjudicated event of definite worsening CHF (PLB
 4 [3.5%], RSG n 5 [4.5%]; p 0.858). Two patients
1.8%) in the RSG group and none in the PLB group
xperienced possible worsening of CHF (Table 2).
There were more cardiovascular hospitalizations in the
SG group than in the PLB group, although the difference
etween treatment groups was not significant (p  0.465)
Table 2). The main reasons for cardiovascular hospitaliza-
ion included worsening CHF (PLB n  9 [7.9%], RSG
 9 [8.2%]), myocardial infarction (PLB n 0, RSG n
[4.5%]) and stroke/transient ischemic attack (PLB n  2
1.8%], RSG n  2 [1.8%]). Both new or worsening edema
nd dyspnea were reported more frequently in the RSG
roup compared with PLB, although the difference between
roups only reached significance for edema (p  0.005).
he majority of edema and dyspnea events were not
ssociated with adjudicated events of definite or possible
orsening of CHF (Fig. 2). Significantly more patients in
he RSG group had an increased use of CHF medications
ompared with PLB (p  0.037), primarily as a result of
ncreased diuretic use (RSG 28 patients [25.5%], PLB 16
atients [14.0%]).
YHA CHF class changes from baseline: weight gain
nd changes in serum creatinine, hemoglobin, and he-
atocrit. There was no change in the NYHA functional
lass from baseline to week 52 in the majority of patients in
oth groups; NYHA functional class was unchanged in 74
atients (77.9%) in the RSG group and in 81 patients
78.6%) in the PLB group. Worsening of NYHA functional
lass occurred in a similar number of patients in both
Figure 1 Mean BNP Concentrations at Baseline and at
Week 52 in Both Treatment Groups (ITT Population)
*Geometric mean  SE. Data were log-transformed, and then mean and
mean  SE were exponentiated to original scale. Open bars  rosiglitazone
(n 71); solid bars  placebo (n  74). BNP  brain natriuretic peptide;
ITT  intent-to-treat.roups, namely in 16 (16.8%) taking RSG and in 1817.5%) taking PLB. A small proportion improved during
he study: 5 patients (5.3%) taking RSG and 4 patients
3.9%) taking PLB.
At week 52, weight had increased more in the RSG
roup (1.3  4.8 kg) compared with the PLB group
0.3  3.2 kg). There were no clinically or statistically
ignificant changes from baseline in either treatment group
r between groups in mean systolic and diastolic blood
ressure, nor in mean heart rate. There was no change in
erum creatinine in either group (change from baseline:
SG 0.3 2.4 mol/l, PLB3.3 2.0 mol/l), although
n the RSG group there was evidence of a small reduction
rom baseline in both hemoglobin (RSG 1.19  1.10
/dl, PLB 0.13 0.84 g/dl) and hematocrit (RSG3.80
.42%; PLB 0.15  2.79%).
iscussion
he primary objective of this study was to investigate the
ffects of RSG on cardiac structure and function in patients
ith T2DM and pre-existing CHF (NYHA functional
lass I to II). The results show that the use of RSG over a
eriod of 1 year was not associated with any significant
hanges in left ventricular volumes, LVEF, or cardiac index.
imilar findings have been reported in a diabetic patient
ohort without CHF who also were treated with RSG for
2 weeks (14). The interpretation of the LVMI data in this
tudy is limited by the small number of evaluable images
vailable, but previous studies have not suggested that RSG
s associated with progression of left ventricular hypertrophy
n humans (14).
The patients recruited into the present study were similar
n terms of the distribution of age and gender to those
ecruited in previous studies of CHF (15,16). They had
ild to moderately severe symptoms of heart failure and a
Figure 2 Adjudicated Events of Edema and Dyspnea
Occurring With or Without Worsening CHF
Open bars  patients with adjudicated event of edema or dyspnea occurring
without a concomitant event of definite or possible worsening of chronic heart
failure (CHF); solid bars  patients with adjudicated event of edema or dys-
pnea occurring with a concomitant event of definite or possible worsening of
CHF. PLB  placebo; RSG  rosiglitazone.
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April 24, 2007:1696–704 Rosiglitazone and NYHA Class I or II CHFoderately reduced mean LVEF. All were taking either an
ngiotensin-converting enzyme inhibitor or an angiotensin
eceptor blocker, and although not a requirement, 70% were
lso taking a beta-blocker. Because of regulatory safety
oncerns, patients with class III to IV CHF were excluded
rom this study.
Approximately one-quarter of patients in both treatment
roups withdrew from the study; as expected, more patients
aking PLB withdrew because of insufficient therapeutic
ffect compared with those taking RSG. Nevertheless, the
tudy retained at least 90% power to assess the primary end
oint. In addition, the EE population with evaluable
CHO data closely matched the ITT population.
Although improvements in glycemic control and insulin
ensitivity may have contributed to improved myocardial
etabolism (17), there was no evidence from this study that
his led to an improvement in cardiac function after 1 year
f treatment with RSG. Linear regression analysis also
howed no relationship between a change in HbA1c and a
hange in LVEF, which is consistent with the literature in
general diabetic population (18). However, the lack of an
ssociation between changes in HbA1c and LVEF in our
ataset may have occurred because of the comparatively
mall number of patients studied, the modest improvement
n glycemia, or the relatively short duration of the study.
he BNP increased slightly from baseline in the RSG
roup, suggesting that the fluid retention observed in this
roup also was associated with an increase in left ventricular
all stress despite no change in mean LVEDVI. The LVEF
id not deteriorate in the PLB group, probably reflecting
he high standards of care and the use of multiple CHF
edications for all patients in this study. The clinical
elevance of a small but statistically significant increase from
aseline of 20 pg/ml BNP in the RSG group during the
tudy is unclear. Although the increase in BNP may have
ccurred in response to increased left ventricular strain as a
esult of thiazolidinedione-induced plasma volume expan-
ion, an increase in end-diastolic volume was not observed
n ECHO. An alternative explanation is that the increase in
NP may reflect regression to the mean from a low baseline
alue. More studies are needed to understand the clinical
mplications, if any, of small changes in BNP in this
igh-risk population.
The NYHA functional class was assessed both at screen-
ng and at week 52, and showed no change for the majority
f patients within each treatment group and no differences
etween treatment groups. These data are consistent with
he ECHO data, which probably excluded any major
eleterious effect on systolic function in the time frame
tudied. It is important to recognize that physician-
valuated functional status may differ from that determined
y the patients themselves (19). Approximately one-quarter
f the patients developed some fluid-related symptoms or
igns, and almost one-third required an increase in CHF
edications during the course of the study. The increasedse of CHF medications may explain the stability of ECHO carameters over the 1-year treatment period, and also the
tability of NYHA functional class at study end compared
ith baseline, despite the development of fluid-related
vents in both treatment groups during the study.
Clinical end point data relating to cardiovascular events
ere collected by the investigators and independently and
onsistently adjudicated by a panel of experts. It should be
oted that the study was powered to evaluate left ventricular
unction by ECHO rather than the effect of RSG on clinical
nd points. There were no statistically significant between-
roup differences for major events such as all-cause mortal-
ty, cardiovascular death, or hospitalization for worsening
HF. Although this study was not powered to definitively
how potential treatment differences in other (fluid-related)
djudicated end points, more fluid-related events were
djudicated to have occurred in the RSG group than in the
LB group. Significantly more events of new or worsening
dema and increased CHF medication occurred in the RSG
roup, although there was no significant difference between
roups in the incidence of dyspnea or any other adjudicated
nd points, including cardiovascular hospitalization. Bear-
ng in mind the similar rates of withdrawal from the study
n both treatment groups, it is reasonable to conclude that
ost fluid-related events were managed by investigators in
he clinic using standard medications. Regular visits every 4
o 8 weeks ensured that patients were monitored for fluid
etention and that this was managed appropriately to
revent clinical worsening. Importantly, renal function, as
etermined by serum creatinine, did not deteriorate despite
he increased use of diuretics.
Awareness of left ventricular diastolic dysfunction is
ncreasing among physicians, and it is a problem that may
e particularly important for T2DM patients (20). One case
eries has also suggested that diabetic patients with diastolic
ysfunction may be at risk of developing CHF with thia-
olidinediones (12). Although in this study transmitral flow
elocities were measured using pulsed Doppler, changes in
lasma volume either with the use of RSG or changes in the
ose of diuretics used limit the interpretation of these data.
uture studies, ideally in people with normal systolic func-
ion, could assess potential changes in diastolic function
ssociated with thiazolidinediones, but these studies will
equire the use of novel imaging techniques that account for
eft atrial pressure changes.
Recently published data suggest that thiazolidinediones
ay be associated with an improvement in cardiovascular
utcomes in stable T2DM patients without overt heart
ailure (21). For the individual patient with T2DM and
HF, these potential benefits should be weighed against the
otential risks from fluid retention. This study was not
esigned to evaluate the potential for RSG to improve
ardiovascular outcomes in patients with NYHA functional
lass I to II CHF. However, it confirms that the use of RSG
n such patients resulted in an improvement in glycemic
ontrol, although approximately one-third of patients
t
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Rosiglitazone and NYHA Class I or II CHF April 24, 2007:1696–704reated with RSG required a change in medication to treat
uid retention.
Patients with NYHA functional class I to II CHF treated
ith RSG need to be supervised and managed carefully to
void deterioration of their functional status, and in this
tudy patients were seen every 4 to 8 weeks. These data
upport the recommendations suggested by the Joint Amer-
can Heart Association/American Diabetes Association
onsensus Statement regarding thiazolidinedione use (7).
n patients with impaired left ventricular systolic function,
he dose of RSG should be increased cautiously while
bserving for signs of CHF. In the event that worsening
ymptoms of CHF occur, the use of standard CHF thera-
ies is advocated and the dose of RSG may need to be
educed or temporarily/permanently discontinued.
onclusions
fter 52 weeks of treatment, RSG in addition to back-
round antidiabetes medication was associated with an
mprovement in glycemic control and did not adversely
ffect LVEF, left ventricular volumes, cardiac index, or
ransmitral Doppler flow parameters as determined by
CHO in T2DM patients with pre-existing CHF (NYHA
unctional class I to II). However, there was a higher
ncidence of fluid-related end points during treatment with
SG. Most of the fluid-related events did not lead to early
ithdrawal of patients from the study. The majority of
vents were managed in the clinic by the timely and
ppropriate use of diuretics.
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